

DAFTAR PUSTAKA

1. Gudjonsson J, Elder J. Psoriasis. Dalam: Wolff K, Katz S, Gilchrest B, Paller A, Leffel D, eds. Fitzpatrick Dermatology in general medicine. New York: McGraw Hill; 2008:169-92.
2. Takahashi H, Lizuka H. Psoriasis and metabolic syndrome. Journal of Dermatology 2011;38:1-7.
3. Barker JN. Genetic aspect of psoriasis. Clin and Exp Dermatol 2001;26:321-25.
4. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenereol Croat 2010;18:297-304.
5. Alsufyani M, Golant A, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatologic Therapy 2010;23.
6. World Health Organisation. Global report on psoriasis. World Health Organisation. 2016
7. Schön M, Boehncke W. Psoriasis. N Engl J Med 2005; 352:1899-912.
8. Ommen P, Stjernholm T, Kragstrup Tl. The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. Br J Dermatol. 2016;174(1):187-190.
9. Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM. Leptin levels in patients with psoriasis: A meta-analysis. Clin Exp Dermatol. 2013;38(5):478-483.



10. Baran A, Flisiak I, Jaroszewicz J, Widerska M. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. *J Dermatolog Treat.* 2015;26(2):954-6634.
11. Oh YJ, Lim HK, Choi JH, Lee JW, Kim NI. Serum leptin and adiponectin levels in Korean patients with psoriasis. *J Korean Med Sci.* 2014;29(5):729-734.
12. Li RC, Krishnamoorthy P, Derohannessian S. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. *Clin Exp Dermatol.* 2014;39(1):19-24.
13. Lasendra D, Raspati H, Setiabudiawan B. Hubungan antara kadar leptin serum dan manifestasi penyakit atopik pada anak obes. *Sari Pediatri,* 2015:35-40.
14. Silverberg JI, Silverberg N.B, Wong ML. Association between atopic dermatitis and obesity in adulthood. *BJD* 2012: 498-504
15. Karadag AS, Ertugrul DT, Takci Z. The effect of isotretinoin on retinol-binding protein 4, leptin, adiponectin and insulin resistance in acne vulgaris patient. *Dermatology* 2015:1-5.
16. Xue K, Liu H, Jian Q. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index. *Exp Dermatol.* 2013: 406-410.

17. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbaşı MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. *Br J Dermatol*. 2008;159(4):820-826.
18. Baran A, Flisiak I, Jaroszewicz J, Świdarska M. Effect of psoriasis activity on serum adiponectin and leptin levels. *Postępy Dermatologii i Alergol Postep Derm Alergol*. 2015;2(2):101-106.
19. Madanagobalane S, Sandhya V, Anandan S, Seshadri K. Circulating adiponectin levels in Indian patients with psoriasis and its relation to metabolic syndrome. *Indian J Endocrinol Metab*. 2014;18(2):191.
20. Zyl SV, Merwe Ij, Rooyen FC, Joubert G, Walsh CM. The relationship between obesity, leptin, adiponectin and the component metabolic syndrome in urban African women, Free State, South Africa. *SAJCN* 2017: 68-73.
21. Jaramillo PL, Arbelaez DG, Lopez JL, Lopez CL, Ortega JM, Rodriguez AG, et al. The role of leptin/ adiponectin ratio in metabolic syndrome and diabetes. *Horm Mol Biol Clin Invest* 2013; 1-9.
22. Konsoulova PS, Nyagolova PV, OrbetzovaMM, Simitchiev KK, Terzieva DD, Kaleva NN. Leptin, adiponektin, and leptin/adiponectin ratio in adolescents with metabolic syndrome. *IJPMR* 2016; 1-6.
23. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E. Leptin:adiponektin ratio is an independent predictor of intima media thickness of the common carotid artery. *Stroke* 2007; 38:2844-2846.
24. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features and quality of life. *Ann Rheum Dis* 2005;64:8-23.

25. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. *J. Am Acad Dermatol* 2006;53: 94-100.
26. De Rie M.A, Goedkoop A.Y, Bos J.D. Overview of psoriasis. *Dermatol Ther* 2004;17:341-49.
27. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol* 2009;4: 643-59.
28. Balato A, Balato N, Megna M, Schiattarella M, Lembo S. Pathogenesis of psoriasis: the role pro-inflammatory cytokines produced by keratinocytes. *Clinics in Dermatology* 2009;25: 572–580.
29. Molteni S, Reali E. Biomarkers in the pathogenesis, diagnosis and treatment of psoriasis. *Psoriasis Targets and Therapy* 2012;2:55-66.
30. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. *Clinics in Dermatology* 2007;25: 574–80.
31. Abdelnoor AM. Factors involved in the pathogenesis of psoriasis. *Advanced Studies in Medical Sciences* 2013;1: 75-94.
32. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. *J AM Acad Dermatol* 2002;46: 1-23.
33. Darouti ME, Hay RA. Psoriasis: Highlights on pathogenesis, adjuvant therapy and treatment of resistant and problematic cases part 1. *J Egypt Women Dermatol Soc* 2010 :64-70.

34. Davidovici AA, Sattar N, Jong PC. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *Journal of Investigative Dermatology* 2010;130:1785-1796.
35. Ashcroft DM, Wan PL, Williams HC, Friffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. *Br J Dermatol* 1999;141:185-191.
36. Wauters M, Considine RV, Van Gaal LF. Human leptin: From an adipocyte hormone to an endocrine mediator. *EJE*, 2000; 147: 293-311.
37. Al-Jumaily EF, Zgaer SH. A review: Leptin structure and mechanism actions. *BEPLS* 2014: 185-192.
38. Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong M, Licino J. Leptin: Molecular mechanisms, systemic pro-inflammatory effects and clinical implications. *Arq Bras Endocrinol Metab* 2012: 56-9.
39. Abdel Hay RM, ashed LA. Association between the leptin gene 2548/A polymorphism, the plasma leptin and metabolic syndrome with psoriasis. *Exp Derm* 2011; 715-719.
40. Faggioni R, Feingold KR, Grunfeld C, Leptin regulation of immune response and the immunodeficiency of malnutrition. *The FASEB Journal*, 2001: 2565-2571.
41. Prokop JW, Duff RJ, Ball HC. Leptin and leptin reseptor: Analysis of structure to function relationship in interaction and evolution from humans to fish. *PubMed Central*, 2012: 326-336.

42. Materese G, Montzoros CS. Leptin in immunology. *J Immunol* 2005 and 3137-3142.
43. Safoury, O.E., Fawzy, M.M., Abdel-Hay, R.M., Hassan, A.S., El-Maadawi, Z.M., Rashed, L.A. Increased tissue leptin hormone level and mast cell count in skin tags: a possible role of adipimmune in the growth of benign skin growths. *Indian J Dermatol* 2010: 1-4.
44. Limanan D, Prijanti AR. Hantaran sinyal leptin dan obesitas: Hubungannya dengan penyakit kardiovaskuler. *Journal UI*, 2013:149-155.
45. Maskari MY, Alnaqdy AA. Correlation between serum leptin levels, body mass index and obesity in imanis. *Sultan Qaboos Univ Med J*, 2006:27-31.
46. Bell LN, Considine RV. Leptin and obesity. Dalam: Castracane DV, Henson MC, eds *Leptin. Endocrine Updates*, vol 25. Springer, Boston. 2006.
47. Gerdes S, Yazdi MR, Mrowietz U. Adipokines and psoriasis. *Exp Dermatol* 2011; 81-87.
48. Madanagobalane S, Sandhya V, Anandan S, Seshadri KG. Circulating adiponectin levels in Indian patients with psoriasis and its relation to metabolic syndrome. *IJEM* 2014:18; 191-196.
49. Nedvidkova J, Smitka K, Kopsky V, Hainer V. Adiponectin, an adipocyte-derived protein. *Physiol Res* 2005: 54; 133-140.
50. Fang X, Sweeney G. Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. *biochemical Society Transaction* 2006:34; 798-801.

51. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin receptors in the integrated regulation of metabolic and cardiovascular disease. *IJO* 2008; 13–18.
52. Sertznig P, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) in dermatology. *Dermato-Endocrinology* 2011; 130-135.
53. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, dkk. New insight into adiponectin role in obesity and obesity-related disease. *Biomed Res Int* 2014; 1-14.
54. Matsuzawa Y. Adiponectin and inflammation. Dalam: Fantuzzi, Mazzone T ed. *Nutrition and Health: Adipose and adipokines in health and disease*. Totowa: Humana Press.
55. Gavrilu A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: Comparison with leptin, circulating soluble leptin receptor, and cortisol pattern. *J Clin Endocrinol Metab* 2003: 2838-2843.
56. Zayed AA, Maksoud NA, Ragab HM. Psoriasis vulgaris severity and body mass index: evaluating the role of leptin, tumor necrosis factor- α , and interleukin-6. *J Egypt Woman Dermatol Soc* 2012; 88-91.
57. Al-Dhalimi MA, Al-Sahlawee MMR, Al-Sawee HKF. Correlation of leptin with severity of plaque psoriasis in Iraqi male patients. *IASJ* 2016:1461-1468.
58. Oh YJ, Lim HK, Choi JH, Lee JW, Kim NI. Serum leptin and adiponectin levels in Korean patients with psoriasis. *J Korean Med Sci* 2014:729-734.

59. Sereflican B, Goksugur N, Bugdayci G, Polat M, Parlak AH. Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF- α) levels in patients with psoriasis and their correlation with disease severity. *Acta Dermatovenerol Croat* 2016: 13-19.
60. Siniah B, Devi PSS, Prashath DDB. Epidemiology of psoriasis in Malaysia: A hospital based study. *Med J Malaysia* 2010: 112-115.
61. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis over three decades: A population based study. *J Am Acad Dermatol* 2009: 394-401.
62. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systemic review of incidence and prevalence. *J. Investig. Dermatol.* 2013 : 377-385.
63. Moselhy EA, Nada IS, Khalifa HO, Hassan HM, Alrhman RM. Psoriasis and psoriatic arthritis characteristics and risk factors among adult patients in egypt. *Egyptian Journal* 2012: 301-320.
64. Pane HN, Tanjung C, Nababan KA. Serum leptin levels profile in various severity psoriasis vulgaris patients in Haji Adan Malik Hospital Medan. Didownload pada <http://repository.usu.ac.id/bitstream/handle/123456789/51129/Cover.pdf;jsessionid=2F47201A2684AB94176CEACA4117ECE5?sequence=7>.
65. Chang ML, Chen TH, Hsu CM, Lin CH, Lin CY, Jung Kuo C. The evolving interplay among abundant adipokines in patients with hepatitis C during viral clearance. *Nutrients* 2017: 1-9.

66. Aktan S, Rota S, Erdogan BS, Regin S, Kaptanoglu B, Bostanci M. A role of leptin in psoriasis. *Turk J Med Sci* 2007: 135-138.
67. Likuni N, Kwan Lam QL, Lu L, Matarese G, Cava AL. Leptin and inflammation. *Curr Immunol Rev* 2008: 70-79.
68. Melnik BC. Is sebocyte-derived leptin the missing link between hyperseborrhea, ductal hypoxia, inflammation and comedogenesis in acne? *Experimental Dermatology*, 2016: 181-182.
69. Melnik BC, Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. *Clinical, Cosmetic and Investigational Dermatology*, 2015: 371-388.
70. Napolitano M, Megna M, Monfrecola G. Insuline Resistance and Skin Diseases. *The Scientific World Journal* 2015 and 1-11.
71. Takashi H, Ilzuka H. Prosiasis and metabolic syndrome. *Journal of dermatology* 2012: 212-218.
72. Ouchi N, Walsh K. Adiponectin as anti inflammatory factors. *Clin Chin Acta* 2007: 1-14.
73. Fantuzzi G. Adiponectin and inflammation: Consensus and controversy. *J allergy Clin Immunol* 2008: 326-330.
74. Ling XJ, Xin MH, Lu H, Xian W, Lin Z. Serum ratio of leptin to adiponectin in patients with chronic periodontitis and type 2 diabetes mellitus. *ISRN Biomarkers* 2014: 1-5.

75. Vasilescu R, Ifrim S, Tirgoviste CI. Leptin to adiponectin ratio in an independent predictor of common carotid artery intima-media thickness in obese subjects. Proc Rom Acad 2010: 209-217.

